121 related articles for article (PubMed ID: 7522581)
1. Three-dimensional model of the BR96 monoclonal antibody variable fragment.
Bajorath J
Bioconjug Chem; 1994; 5(3):213-9. PubMed ID: 7522581
[TBL] [Abstract][Full Text] [Related]
2. The x-ray structure of an anti-tumour antibody in complex with antigen.
Jeffrey PD; Bajorath J; Chang CY; Yelton D; Hellström I; Hellström KE; Sheriff S
Nat Struct Biol; 1995 Jun; 2(6):466-71. PubMed ID: 7664109
[TBL] [Abstract][Full Text] [Related]
3. A combinatorial library strategy for the rapid humanization of anticarcinoma BR96 Fab.
Rosok MJ; Yelton DE; Harris LJ; Bajorath J; Hellström KE; Hellström I; Cruz GA; Kristensson K; Lin H; Huse WD; Glaser SM
J Biol Chem; 1996 Sep; 271(37):22611-8. PubMed ID: 8798431
[TBL] [Abstract][Full Text] [Related]
4. Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis.
Yelton DE; Rosok MJ; Cruz G; Cosand WL; Bajorath J; Hellström I; Hellström KE; Huse WD; Glaser SM
J Immunol; 1995 Aug; 155(4):1994-2004. PubMed ID: 7636250
[TBL] [Abstract][Full Text] [Related]
5. Comparison of an antibody model with an X-ray structure: the variable fragment of BR96.
Bajorath J; Sheriff S
Proteins; 1996 Feb; 24(2):152-7. PubMed ID: 8820482
[TBL] [Abstract][Full Text] [Related]
6. Identification of residues in the monoclonal antitumor antibody L6 important for binding to its tumor antigen.
Stenzel-Johnson PR; Yelton D; Bajorath J
Biochemistry; 1994 Dec; 33(48):14400-6. PubMed ID: 7526900
[TBL] [Abstract][Full Text] [Related]
7. Molecular modeling and site-directed mutagenesis of an anti-phosphotyrosine antibody predicts the combining site and allows the detection of higher affinity interactions.
Ruff-Jamison S; Glenney JR
Protein Eng; 1993 Aug; 6(6):661-8. PubMed ID: 7694275
[TBL] [Abstract][Full Text] [Related]
8. A therapeutic human anti-idiotypic antibody mimics CD55 in three distinct regions.
Spendlove L; Li L; Potter V; Christiansen D; Loveland BE; Durrant LG
Eur J Immunol; 2000 Oct; 30(10):2944-53. PubMed ID: 11069077
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor antibody BR96 blocks cell migration and binds to a lysosomal membrane glycoprotein on cell surface microspikes and ruffled membranes.
Garrigues J; Anderson J; Hellström KE; Hellström I
J Cell Biol; 1994 Apr; 125(1):129-42. PubMed ID: 7511141
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of the disulfide-stabilized Fv fragment of anticancer antibody B1: conformational influence of an engineered disulfide bond.
Almog O; Benhar I; Vasmatzis G; Tordova M; Lee B; Pastan I; Gilliland GL
Proteins; 1998 May; 31(2):128-38. PubMed ID: 9593187
[TBL] [Abstract][Full Text] [Related]
11. [Expression, structure prediction and functional analysis of murine single-chain fragment variable antibody against human cervical cancer].
Wang Y; Li X; Chen W
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jan; 26(1):16-21. PubMed ID: 16495168
[TBL] [Abstract][Full Text] [Related]
12. Chimerization of LL2, a rapidly internalizing antibody specific for B cell lymphoma.
Leung SO; Shevitz J; Pellegrini MC; Dion AS; Shih LB; Goldenberg DM; Hansen HJ
Hybridoma; 1994 Dec; 13(6):469-76. PubMed ID: 7737671
[TBL] [Abstract][Full Text] [Related]
13. Molecular recognition of a peptide mimic of the Lewis Y antigen by an anti-Lewis Y antibody.
Murali R; Kieber-Emmons T
J Mol Recognit; 1997; 10(6):269-76. PubMed ID: 9770651
[TBL] [Abstract][Full Text] [Related]
14. Human IgG1 Cgamma1 domain is crucial for the bioactivity of the engineered anti-CD20 antibodies.
Geng S; Feng J; Li Y; Kang X; Sun Y; Gu X; Huang Y; Chang H; Shen BF
Cell Mol Immunol; 2007 Apr; 4(2):121-5. PubMed ID: 17484806
[TBL] [Abstract][Full Text] [Related]
15. Analysis of BR96 binding sites for antigen and anti-idiotype by codon-based scanning mutagenesis.
Rosok MJ; Eghtedarzadeh-Kondri M; Young K; Bajorath J; Glaser S; Yelton D
J Immunol; 1998 Mar; 160(5):2353-9. PubMed ID: 9498776
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity of chimeric (human-murine) monoclonal antibody BR96 IgG, F(ab')2, and Fab' conjugated to Pseudomonas exotoxin.
Siegall CB; Gawlak SL; Chin JJ; Zoeckler ME; Kadow KF; Brown JP; Braslawsky GR
Bioconjug Chem; 1992; 3(4):302-7. PubMed ID: 1390985
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies.
Wang X; Campoli M; Ko E; Luo W; Ferrone S
J Immunol Methods; 2004 Nov; 294(1-2):23-35. PubMed ID: 15604013
[TBL] [Abstract][Full Text] [Related]
18. Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart.
Cheetham GM; Hale G; Waldmann H; Bloomer AC
J Mol Biol; 1998 Nov; 284(1):85-99. PubMed ID: 9811544
[TBL] [Abstract][Full Text] [Related]
19. Effect of VK framework-1 glycosylation on the binding affinity of lymphoma-specific murine and chimeric LL2 antibodies and its potential use as a novel conjugation site.
Leung SO; Dion AS; Pellegrini MC; Losman MJ; Grebenau RC; Goldenberg DM; Hansen HJ
Int J Cancer; 1995 Feb; 60(4):534-8. PubMed ID: 7829269
[TBL] [Abstract][Full Text] [Related]
20. Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only.
Tamura M; Milenic DE; Iwahashi M; Padlan E; Schlom J; Kashmiri SV
J Immunol; 2000 Feb; 164(3):1432-41. PubMed ID: 10640759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
